



## The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

J Sieper, M Rudwaleit, X Baraliakos, J Brandt, J Braun, R Burgos-Vargas, M Dougados, K-G Hermann, R Landewé, W Maksymowych and D van der Heijde

*Ann Rheum Dis* 2009;68;ii1-ii44  
doi:10.1136/ard.2008.104018

---

Updated information and services can be found at:  
[http://ard.bmj.com/cgi/content/full/68/Suppl\\_2/ii1](http://ard.bmj.com/cgi/content/full/68/Suppl_2/ii1)

---

*These include:*

### References

This article cites 24 articles, 13 of which can be accessed free at:  
[http://ard.bmj.com/cgi/content/full/68/Suppl\\_2/ii1#BIBL](http://ard.bmj.com/cgi/content/full/68/Suppl_2/ii1#BIBL)

### Rapid responses

You can respond to this article at:  
[http://ard.bmj.com/cgi/eletter-submit/68/Suppl\\_2/ii1](http://ard.bmj.com/cgi/eletter-submit/68/Suppl_2/ii1)

### Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

---

### Notes

---

To order reprints of this article go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Annals of the Rheumatic Diseases* go to:  
<http://journals.bmj.com/subscriptions/>

# The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

J Sieper,<sup>1</sup> M Rudwaleit,<sup>1</sup> X Baraliakos,<sup>2</sup> J Brandt,<sup>3</sup> J Braun,<sup>2</sup> R Burgos-Vargas,<sup>4</sup> M Dougados,<sup>5</sup> K-G Hermann,<sup>6</sup> R Landewé,<sup>7</sup> W Maksymowych,<sup>8</sup> D van der Heijde<sup>9</sup>

<sup>1</sup>Rheumatology, Medizinische Klinik I, Charité – Campus Benjamin Franklin, Berlin, Germany; <sup>2</sup>Rheumazentrum Ruhrgebiet, Herne, Germany; <sup>3</sup>Rheumatology Private Practice, Berlin, Germany; <sup>4</sup>University of Mexico City, Mexico City, Mexico; <sup>5</sup>Hospital Cochin, Paris, France; <sup>6</sup>Radiology, Charité – Campus Mitte, Berlin, Germany; <sup>7</sup>Maastricht University Medical Center, Maastricht, The Netherlands; <sup>8</sup>University of Alberta, Edmonton, Alberta, Canada; <sup>9</sup>Leiden University Medical Center, Leiden, The Netherlands

Correspondence to: J Sieper, Charité – Campus Benjamin Franklin, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany; [joachim.sieper@charite.de](mailto:joachim.sieper@charite.de)

Accepted 6 March 2009

## ABSTRACT

The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition of outcome parameters for clinical trials. In the present work, the Assessment in SpondyloArthritis international Society (ASAS) provides a comprehensive handbook on the most relevant aspects for the assessments of spondyloarthritis, covering classification criteria, MRI and x rays for sacroiliac joints and the spine, a complete set of all measurements relevant for clinical trials and international recommendations for the management of SpA. The handbook focuses at this time on axial SpA, with ankylosing spondylitis (AS) being the prototype disease, for which recent progress has been faster than in peripheral SpA. The target audience includes rheumatologists, trial methodologists and any doctor and/or medical student interested in SpA. The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies.

The field of spondyloarthritis (SpA) has faced tremendous changes over the last decade. Undoubtedly, these changes were triggered by the development of several effective therapies for ankylosing spondylitis (AS). Drug development and registration nowadays requires appropriate classification criteria to sharply delineate the trial population of interest as well as a validated toolset for measuring outcome of clinical trials.

The Assessment of SpondyloArthritis international Society (ASAS) (formerly ASessment in Ankylosing Spondylitis), was initiated in 1995 to bring evidence-based unity in the multitude of assessments in the field of AS, has broadened its scope to the entire spectrum of SpA later on, and has extended its work to measuring treatment response in clinical trials, the re-evaluation of existing classification criteria and the development of diagnostic criteria for SpA. This all to achieve the mission of ASAS, which is the support and promotion of translational and clinical research of spondyloarthritis. The ultimate goal is to improve the well-being and outcome of patients with spondyloarthritis. The means to achieve this goal include: (1) increasing awareness of spondyloarthritis, (2) facilitating early diagnosis, (3) developing and validating assessment tools and (4) evaluating treatment modalities. ASAS, which is a worldwide forum consisting of clinical

rheumatologists, methodologists, workers in pharmaceutical industry and others, has always collaborated with organisations such as the Outcome Measures In Rheumatology Clinical Trials (OMERACT) group and the European League Against Rheumatism (EULAR).

One of the first ASAS efforts was the delineation of relevant domains of outcome in AS and the development of a core set of outcome measures to be used in clinical trials (for physiotherapy and disease-modifying antirheumatic drugs (DMARDs)) and in clinical practice (core set for clinical record keeping). Since then, the core set has been updated regularly and there has not been a single field in outcome assessment that ASAS has not addressed. Important achievements with relevant implications have been the development of response criteria for clinical trials (ASAS20, ASAS40, ASAS 5/6 and ASAS partial remission), the validation of measurement instruments for radiographic damage and progression and for magnetic resonance inflammation, and recently the development of a new index for measuring disease activity, the Ankylosing Spondylitis Disease Activity Score (ASDAS).

Since 1995, ASAS-endorsed assessments and response measures have been applied in several clinical trials in AS and SpA and have proven to be extremely valuable in the evaluation of pharmaceutical and non-pharmaceutical treatments and in drug registration.

The ASAS handbook in front of you reads like a compendium of ASAS history. It provides a complete picture of all measurements that have been investigated and developed during the last 13 years, including the ASAS core set. It provides insight in available and newly developed criteria for classifying SpA and it exemplifies response criteria as well as recent achievements in measuring disease activity. Moreover, there is extensive focus on abnormalities seen on imaging (mainly radiographs and MRI) in sacroiliac (SI) joints and spine; features characteristic for SpA, but also caveats that can easily be misinterpreted. New definitions on how to define a positive MRI are also provided.

The handbook focuses on axial SpA, since the development of outcome assessment started in AS, the prototype disease in the spectrum of SpA. Peripheral SpA is not ignored at all, but the picture for this disease is not yet complete and the handbook will be updated once new developments in this field have been substantiated.

The target audience for the ASAS handbook includes every rheumatologist who is interested in

measuring and monitoring patients with SpA in clinical practice as well as clinical researchers in the field of SpA, since it gives detailed descriptions of how tests should be performed. Trial methodologists and other workers in the pharmaceutical industry assigned to the development and conduct of clinical trials will find which outcome measures to choose in trials, how to describe them in the protocol and how to practically teach and use them in the trial. Workers in the regulatory field may use the handbook as a guide to judge the trial performance and robustness. And medical students will find a quick overview of what is important in the field of outcomes in SpA.

Although the handbook aims to be comprehensive in terms of content, the focus is on practicality rather than on understanding background and performance. The reader of the handbook will, for example, find how to perform the modified Schober test or how to score radiographs according to the modified Stoke Ankylosing Spondylitis Spine Score (SASSS), but will not be informed about the relative performance of this test or method in comparison with others. More information on this can be found in the reference list.

The ASAS handbook is published by—and under the responsibility of—the ASAS executive committee, and will be regularly updated.

#### PART A: CLASSIFICATION CRITERIA

In this section all recent classification criteria for spondyloarthritis are listed, starting with the 1984 modified New York criteria for ankylosing spondylitis, followed by the 1990/1991 Amor criteria and the European Spondyloarthropathy Study Group (ESSG) criteria for spondyloarthritis, which cover the

#### Box 1 Modified New York criteria for ankylosing spondylitis (1984)<sup>3</sup>


- ▶ **Clinical criteria:**
    - Low back pain and stiffness for more than 3 months that improves with exercise, but is not relieved by rest.
    - Limitation of motion of the lumbar spine in the sagittal and frontal planes.
    - Limitation of chest expansion relative to normal values correlated for age and sex.
  - ▶ **Radiological criterion:**
    - Sacroiliitis grade  $\geq 2$  bilaterally or grade 3–4 unilaterally.
- Definite AS if the radiological criterion is associated with at least one clinical criterion

#### Box 2 Amor criteria for spondyloarthritis<sup>4</sup>


Criterion	Points
<b>Clinical symptoms or past history:</b>	
Lumbar or dorsal pain during the night, or morning stiffness of lumbar or dorsal spine	1
Asymmetric oligoarthritis	2
Buttock pain	1
if affecting alternately the right or the left buttock	2
Sausage-like toe or digit (dactylitis)*	2
Heel pain or any other well defined enthesiopathy (enthesitis)*	2
Iritis	2
Non-gonococcal urethritis or cervicitis accompanying, or within 1 month before, the onset of arthritis	1
Acute diarrhoea accompanying, or within 1 month before, the onset of arthritis	1
Presence or history of psoriasis, balanitis, or inflammatory bowel disease (ulcerative colitis or Crohn disease)	2
<b>Radiological finding:</b>	
Sacroiliitis (grade $\geq 2$ if bilateral; grade $\geq 3$ if unilateral)	3
<b>Genetic background:</b>	
Presence of HLA-B27, or familial history of ankylosing spondylitis, Reiter syndrome, uveitis, psoriasis, or chronic enterocolopathies	2
<b>Response to treatment:</b>	
Good response to NSAIDs in less than 48 h, or relapse of the pain in less than 48 h if NSAIDs discontinued	2

\*Terms were added by the authors for clarification, not in the original publication. HLA, human leukocyte antigen; NSAIDs, non-steroidal anti-inflammatory drugs. A patient is considered to have spondyloarthritis if the sum of the point counts is 6 or more. A total point count of five or more classifies for probable spondyloarthritis.

whole spectrum of SpA including axial and peripheral SpA and also the early phase of the disease without chronic x ray changes. The most recent ASAS classification criteria for axial spondyloarthritis were developed for early and established cases and include the MRI technique (active inflammation) as an important tool for early diagnosis. ASAS criteria for peripheral SpA are pending and are currently being developed. For diagnosis in daily clinical practice, a more flexible approach is often necessary than is offered by classification criteria that ask for a clear “yes” or “no” response. A diagnostic algorithm for axial SpA based on calculation of likelihood ratios for the clinical, laboratory and imaging parameters typical for SpA has been proposed recently,<sup>1 2</sup> but was not discussed by ASAS and therefore not included in this handbook. The listed criteria for inflammatory back pain (IBP) have a similar performance and can all be used in daily clinical practice. For the development of the ASAS criteria for axial SpA the ASAS-expert IBP criteria were used.

**Box 3 European Spondyloarthritis Study Group (ESSG) criteria<sup>5</sup>****Box 4 ASAS criteria for classification of axial spondyloarthritis (to be applied in patients with chronic back pain and age at onset of back pain <45 years)<sup>6</sup>**

ASAS classification criteria for axial spondyloarthritis (SpA)  
 In patients with  $\geq 3$  months back pain and age at onset <45 years

**Table 1** Specification of the variables used for the European Spondyloarthritis Study Group (ESSG) criteria<sup>5</sup>

Variable	Definition
Inflammatory spinal pain*	History or present symptoms of spinal pain in back, dorsal, or cervical region, with at least four of the following: (a) onset before age 45, (b) insidious onset, (c) improved by exercise, (d) associated with morning stiffness, (e) at least 3 months duration
Synovitis	Past or present asymmetric arthritis or arthritis predominantly in the lower limbs
Family history	Presence in first-degree or second-degree relatives of any of the following: (a) ankylosing spondylitis, (b) psoriasis, (c) acute uveitis, (d) reactive arthritis, (e) inflammatory bowel disease
Psoriasis	Past or present psoriasis diagnosed by a doctor
Inflammatory bowel disease	Past or present Crohn disease or ulcerative colitis diagnosed by a doctor and confirmed by radiographic examination or endoscopy
Alternating buttock pain	Past or present pain alternating between the right and left gluteal regions
Enthesopathy	Past or present spontaneous pain or tenderness at examination at the site of the insertion of the Achilles tendon or plantar fascia
Acute diarrhoea	Episode of diarrhoea occurring within 1 month before arthritis
Urethritis/cervicitis	Non-gonococcal urethritis or cervicitis occurring within 1 month before arthritis
Sacroiliitis	Bilateral grade 2–4 or unilateral grade 3–4, according to the following radiographic grading system: 0 = normal, 1 = possible, 2 = minimal, 3 = moderate and 4 = ankylosis

\*Equivalent to inflammatory back pain (IBP).

**Table 2** Specification of the variables used for the Assessment of SpondyloArthritis international Society (ASAS) criteria for classification of axial spondyloarthritis<sup>6</sup>

Clinical criterion	Definition
IBP	IBP according to experts (see also Box 5): four out of five of the following parameters present: (1) age at onset < 40 years, (2) insidious onset, (3) improvement with exercise, (4) no improvement with rest, (5) pain at night (with improvement upon getting up)
Arthritis	Past or present active synovitis diagnosed by a doctor
Family history	Presence in first-degree or second-degree relatives of any of the following: (a) ankylosing spondylitis, (b) psoriasis, (c) uveitis, (d) reactive arthritis, (e) inflammatory bowel disease
Psoriasis	Past or present psoriasis diagnosed by a doctor
Inflammatory bowel disease	Past or present Crohn disease or ulcerative colitis diagnosed by a doctor
Dactylitis	Past or present dactylitis diagnosed by a doctor
Enthesitis	Heel enthesitis: past or present spontaneous pain or tenderness at examination at the site of the insertion of the Achilles tendon or plantar fascia at the calcaneus
Uveitis anterior	Past or present uveitis anterior, confirmed by an ophthalmologist
Good response to NSAIDs	At 24–48 h after a full dose of NSAID the back pain is not present anymore or much better
HLA-B27	Positive testing according to standard laboratory techniques
Elevated CRP	CRP above upper normal limit in the presence of back pain, after exclusion of other causes for elevated CRP concentration
Sacroiliitis by x rays	Bilateral grade 2–4 or unilateral grade 3–4, according to the modified New York criteria (see Part C, Box 2)
Sacroiliitis by MRI	Active inflammatory lesions of sacroiliac joints with definite bone marrow oedema/osteitis suggestive of sacroiliitis associated with spondyloarthritis (see also Part B on MRI)

CRP, C-reactive protein; HLA, human leukocyte antigen; IBP, inflammatory back pain; NSAID, non-steroidal anti-inflammatory drug.

## Supplement

**Box 5 IBP according to ASAS experts<sup>7</sup> to be applied in patients with chronic back pain (>3 months)**

- ▶ Age at onset <40 years
  - ▶ Insidious onset
  - ▶ Improvement with exercise
  - ▶ No improvement with rest
  - ▶ Pain at night (with improvement upon getting up)
- The criteria are fulfilled if at least four out of five parameters are present.

**Box 6 Calin criteria for IBP<sup>8</sup>**

- ▶ Age at onset <40 years
  - ▶ Back pain >3 months
  - ▶ Insidious onset
  - ▶ Associated with morning stiffness
  - ▶ Improvement with exercise
- The Calin criteria are fulfilled if at least four out of five parameters are present.

**Box 7 Berlin criteria for IBP<sup>9</sup> to be applied in patients with chronic back pain (>3 months)**

- ▶ Morning stiffness >30 min
  - ▶ Improvement with exercise but not with rest
  - ▶ Awakening at second half of the night because of back pain
  - ▶ Alternating buttock pain
- The criteria are fulfilled if at least two out of four parameters are present.

**PART B: MRI**

MRI studies of the sacroiliac joints and the spine in patients with SpA have made a major contribution in the last decade to a better understanding of the course of the disease, to an early diagnosis and have been used as an objective outcome measure for clinical trials.

Active inflammatory changes are visualised best by fat-saturated T2-weighted turbo spin-echo sequence or a short tau inversion recovery (STIR) sequence with a high resolution (image matrix of 512 pixels, slice thickness of 3 mm or 4 mm), which can detect even minor fluid collections such as bone marrow oedema. Alternatively, administration of a paramagnetic contrast medium (gadolinium) detects increased perfusion (osteitis) in a T1-weighted sequence with fat saturation. These two sequences give largely overlapping information, although occasionally applying both methods can give additional value. Chronic changes such as fatty degeneration and erosions are best seen by using a T1-weighted turbo spin-echo sequence.

MRI of the axial skeleton is performed with whole-body scanners with a field strength of 1.0 or 1.5 Tesla, preferably using special spinal or body phased-array coils. The SI joints are imaged using a semicoronal section orientation along the long axis of the sacral bone. The protocol comprises a T1-weighted

turbo spin-echo sequence, a T2-weighted gradient-echo sequence using the opposed-phase technique and a STIR sequence with slices of 4 mm thickness. The whole sacral bone should be covered from its anterior to its posterior border, which usually requires at least 10–12 slices. Administration of a paramagnetic contrast medium (gadolinium), usually followed by imaging with a fat-saturated T1-weighted turbo spin-echo sequence, might give additional information on active inflammation.

An efficient spinal imaging protocol comprises a sagittal T1-weighted turbo spin-echo sequence and a sagittal fat-saturated T2-weighted turbo spin-echo sequence, or STIR sequence with a high resolution. If a paramagnetic contrast medium is administered, a T1-weighted sequence with fat saturation should be used in a sagittal orientation. Transverse slices are useful for assessment of the posterior parts of the spine. However, for routine imaging of the spine transverse sequences are time consuming and therefore less feasible. Coronal slices of the entire spine may be used for better assessment of the costovertebral and costotransverse joints and of the facet joints.

In the following section, a detailed description of active inflammatory and chronic lesions of the sacroiliac joints and the spine typical for SpA is given, with many examples of images. Because active inflammation of the SI joints has become an important parameter for early diagnosis of axial SpA, special emphasis has been given to define a “positive lesion”. Furthermore, pitfalls in the diagnosis of SpA-specific MRI findings are discussed and shown.

Before assessing the active inflammatory or chronic lesions on MRI it is necessary to define the MRI sequence of the image in question. This can normally be done by looking at spinal fluid, intervertebral discs and subcutaneous fat tissue (see Box 8).

Several scoring methods for assessing inflammatory activity in the spine and sacroiliac joints have been used in the past and have also recently been compared with each other.<sup>10 11</sup> However, none of them has been proven so far to be superior. Therefore, these scores have not been included in this handbook at this time point but may be added later on.

**Box 8 Signal characteristics of MRI sequences used for the imaging of spine and sacroiliac joints**

Sequence	Spinal fluid (water content)	Intervertebral disc (water content)	Subcutaneous fat tissue	Active inflammatory lesions
T1-weighted	Hypointense <sup>1</sup>	Hypointense <sup>1</sup>	Hyperintense <sup>1</sup>	Hypointense <sup>1</sup>
T1-weighted post-gadolinium	Hypointense <sup>2</sup>	Hypointense <sup>2</sup>		Hyperintense <sup>2</sup>
With fat saturation			Hypointense <sup>2a</sup>	
Without fat saturation (not recommended)			Hyperintense <sup>2b</sup>	
Short tau inversion recovery (STIR)	Hyperintense <sup>3</sup>	Hyperintense <sup>3</sup> (hypointense if disc is degenerative)	Hypointense <sup>3</sup>	Hyperintense <sup>3</sup>

**Examples:**

<sup>1</sup>MRI sacroiliac joints (Box 18, A), spine (fig 1A).

<sup>2</sup>MRI (a) sacroiliac joints (Box 11), (b) spine (fig 1B).

<sup>3</sup>MRI sacroiliac joints (Box 10, A-F), spine (fig 1C).


**I. MRI OF THE SACROILIAC JOINTS IN PATIENTS WITH SPONDYLOARTHRITIS<sup>12</sup>****Box 9 Types of typical MRI lesions of the sacroiliac joint**

- ▶ Active inflammatory lesions (STIR/post-gadolinium T1):
  - bone marrow oedema (osteitis)
  - capsulitis
  - synovitis
  - enthesitis
- ▶ Chronic inflammatory lesions (normally T1):
  - sclerosis
  - erosions
  - fat deposition
  - bony bridges/ankylosis

## Box 10 Active inflammatory lesions: bone marrow oedema (osteitis)

- ▶ Hyperintense signal on STIR images (bone marrow oedema) and/or on contrast-enhanced T1-weighted fat-saturated images (osteitis). The stronger the hyperintense signal the more likely it reflects active inflammation (intensity of the hyperintense signal is similar to that of blood vessels or spinal fluid).
- ▶ Bone marrow oedema (BME) is an indicator of active sacroiliitis but may be found in other pathologies as well.
- ▶ Affected bone marrow areas are located periarticularly.
- ▶ BME may be associated with structural changes such as erosions.

A–E. Bone marrow oedema/osteitis: affected bone marrow areas (arrows) are located periarticularly (short tau inversion recovery (STIR)). F. Bone marrow oedema/osteitis: bone marrow oedema may be associated with structural changes such as erosions (arrow) (STIR). B and D have been reproduced from Rudwaleit.<sup>12</sup>



**Box 11 Active inflammatory lesions: synovitis**

- ▶ Synovitis is reflected by hyperintense signals on contrast-enhanced T1-weighted fat-saturated images in the synovial part of the SI joints (similar to blood vessels). STIR sequences do not differentiate between synovitis and joint fluid.
- ▶ Synovitis on MRI as a single feature (without BME) is a rare finding and may not suffice for making an imaging diagnosis of sacroiliitis.



Synovitis (arrows) of both sacroiliac joints (contrast-enhanced T1-weighted fat-saturated images). This figure has been reproduced from Rudwaleit.<sup>12</sup>

**Box 12 Active inflammatory lesions: capsulitis**

- ▶ Capsulitis is comparable to synovitis in terms of signal characteristics but these changes involve the anterior and posterior capsule. Anteriorly, the joint capsule gradually continues into the periosteum of the iliac and sacral bones and thus corresponds to an enthesis. Capsulitis, therefore, may extend far medially and laterally into the periosteum. Capsulitis may be better detectable using contrast-enhanced T1-weighted fat-saturated images as compared to STIR.




Capsulitis (arrows) (contrast-enhanced T1-weighted fat-saturated images). Osteitis of the right sacroiliac joint (active sacroiliitis) can also be seen in this patient.

This figure has been reproduced from Rudwaleit.<sup>12</sup>

## Box 13 Active inflammatory lesions: enthesitis

- Hyperintense signal on STIR images and/or on contrast-enhanced T1-weighted fat-saturated images at sites where ligaments and tendons attach to bone, including the retroarticular space (interosseous ligaments). The signal may extend to bone marrow and soft tissue. Enthesitis may be better detectable using contrast-enhanced T1-weighted fat-saturated images as compared to STIR.




A. 1: Enthesitis (white arrow) of interosseous ligaments (contrast-enhanced T1-weighted fat-saturated images; coronal view). Also present: osteitis of the left iliac bone (black arrow). 2: Enthesitis (white arrows) of interosseous ligaments (contrast-enhanced T1-weighted fat-saturated images; axial view). Also present: osteitis of the left sacroiliac joint (black arrow). B. 1: Enthesitis (arrow) of interosseous ligaments (short tau inversion recovery (STIR)). 2: Enthesitis (arrow) of interosseous ligaments (STIR). 3: T1-weighted sequence for comparison, same patient as 1. 4: T1-weighted sequence for comparison, same patient as 2.

A1 and A2 have been reproduced from Rudwaleit.<sup>12</sup>

### Box 14 Active inflammatory lesions: differential diagnosis and pitfalls

- ▶ Inflammation of SI joints in SpA is usually limited to the bone/SI joint and does not cross anatomical borders.
- ▶ Other pathologies may result in reactive (secondary) lesions that appear as inflammation.
- ▶ Ligaments surrounded by vessels may appear as actively inflamed.
- ▶ Coil effect (artefact).



## Supplement

## Box 14 Continued

A. 1: Infectious sacroiliitis left sacroiliac (SI) joint with crossing of anatomical border (arrow) (short tau inversion recovery (STIR)). 2: Infectious sacroiliitis left SI with crossing of anatomical border (arrow) (contrast-enhanced T1-weighted fat-saturated images; coronal); same patient as in 1. 3: Infectious sacroiliitis (T1-weighted sequence for comparison); same patient as in 1. B. Infectious sacroiliitis (contrast-enhanced T1-weighted fat-saturated images; axial): inflammation of soft tissue (thin arrows); sacral bone with normal signal (arrowhead). C. 1: Insufficiency fracture (arrows) of the left iliac bone (T1-weighted). 2: Insufficiency fracture of the left iliac bone (same patient) with extensive bone marrow oedema (STIR). D. 1: Coil effect (small arrows) with false positive signals (arrowhead) in the right SI joint (STIR). 2: Coil effect; the false positive signal is not longer visible in the contrast-enhanced T1-weighted fat-saturated image; same patient as in 1. E. 1: Osteosarcoma of the right ileum, timepoint 1 (STIR). 2: Osteosarcoma of the right ileum, timepoint 1 (T1-weighted sequence for comparison). 3: Osteosarcoma of the right ileum, timepoint 2, 6 months later (STIR) (arrow). A1, A3, C1, C2, D1 and D2 have been reproduced from Rudwaleit.<sup>12</sup> E1, E2 and E3 have been reproduced from Song<sup>13</sup> (online version).


### Box 15 How to define active inflammatory lesions ("positive MRI") of the sacroiliac joint (sacroiliitis) associated with spondyloarthritis on MRI

- ▶ The presence of definite subchondral bone marrow oedema/osteitis highly suggestive of sacroiliitis is mandatory.
- ▶ The presence of synovitis, capsulitis, or enthesitis only without concomitant subchondral bone marrow oedema/osteitis is compatible with sacroiliitis but not sufficient for making a diagnosis of active sacroiliitis.
- ▶ Technical aspects: STIR images are usually sufficient to detect active (acute) inflammatory lesions; exception: synovitis (not detectable with STIR only, T1 post-gadolinium is needed).
- ▶ Amount of signal required: if there is one signal (lesion) only, this should be present on at least two slices. If there is more than one signal on a single slice, one slice may be enough.

A: sacroiliitis of the left SI joint (STIR). If there is more than one signal on a single slice, one slice may be enough.

B: sacroiliitis of the left SI joint (STIR). If there is only one signal as shown here (arrow), signals on additional slices would be necessary.

C1-C3: one lesion only present on a single slice (circle, only in C2) is not sufficient (STIR); indicating here a blood vessel (circle in C2).




C2 has been reproduced from Rudwaleit.<sup>12</sup>

### Box 16 Chronic inflammatory lesions: technical aspects

- ▶ T1 sequences are usually sufficient to detect structural lesions (sclerosis, fat deposition, ankylosis).
- ▶ T1 fat-suppressed (T1 FS) or T2 gradient-echo sequences might be better to detect erosions.

### Box 17 Chronic inflammatory lesions: subchondral sclerosis

- ▶ Sclerotic areas are depicted as low-intensity or signal-free bands by all sequences (T1, STIR, T1 post-gadolinium) and show no signal enhancement after contrast medium administration. Sclerosis attributable to SpA should extend at least 5 mm from the SI joint space.




A. 1: Subchondral sclerosis (arrows) of the right sacroiliac (SI) joint (T1). 2: Subchondral sclerosis (arrow) of the right SI joint (short tau inversion recovery (STIR)). B. 1: Subchondral sclerosis of the right sacrum (arrow) (STIR). 2: Subchondral sclerosis of the right sacrum (arrows) without signal enhancement after contrast medium administration (T1 post-gadolinium). C. Subchondral sclerosis (arrow) attributable to SpA should extend at least 5 mm from the SI joint space (STIR). D. Normal variant with sclerosis (arrow) in a healthy 28-year-old person (coronal, T1). E. Normal variant with sclerosis (arrow) in a healthy 28-year-old person (axial, STIR). A1 and A2 have been reproduced from Rudwaleit.<sup>12</sup>

## Supplement

## Box 18 Chronic inflammatory lesions: erosions

- ▶ Erosions are of low signal intensity on T1-weighted images and high signal intensity on STIR images if active. T2 gradient-echo or T1 fat-saturated sequences maybe more useful in detecting erosions.
- ▶ Erosions are bony defects at the joint margin. Erosions may occur throughout the cartilaginous compartment of the joint. Erosions initially appear as single lesions. Confluence of erosions may be seen as pseudodilation of the sacroiliac joints.

A. 1: Irregular shape of the sacroiliac (SI) joint due to erosions (arrows) shown in the T1-weighted sequence. 2: Erosions (arrow) with accompanying inflammation (short tau inversion recovery (STIR)) of the sacroiliac joint. 3: Widening of the sacroiliac joint due to confluent erosions (T2 gradient). Single erosions are difficult to detect. 4: Erosions (arrows) and bone marrow oedema shown in the STIR sequence. All images from the same patient.




A3 and A4 have been reproduced from Song<sup>13</sup> (online version).

## Box 19 Chronic inflammatory lesions: periarticular fat depositions

- ▶ Fat accumulation is characterised on MRI by an increased signal intensity on T1-weighted images.
- ▶ Accumulation results from the esterification of fatty acids in inflammatory, often periarticular bone marrow areas.
- ▶ In general, it is a non-specific finding. In SpA, it often indicates areas of previous inflammation.

A. Periarticular fat depositions (arrows) of sacroiliac (SI) joints (T1-weighted sequence). B. Periarticular fat depositions (arrows) of SI joints (T1-weighted sequence).




A has been reproduced from Rudwaleit.<sup>12</sup>

**Box 20 Chronic inflammatory lesions: ankylosis**

- ▶ Low signal intensity on all MRI sequences, sometimes surrounded by high intensity signal on T1 (fatty degeneration of bone marrow).
- ▶ Bone buds directly facing each other have fused to form bone bridges across the joint.
- ▶ When several adjoining bone bridges are present, the joint cavity becomes increasingly blurred.

A. Small ankylosis of left sacroiliac (SI) joint (circle) (T1-weighted sequence). B. Ankylosis of SI joints (arrows) (T1-weighted sequence)



B has been reproduced from Rudwaleit.<sup>12</sup>

**Box 21 Definition of sacroiliitis highly suggestive of SpA ("positive MRI") for application in the new ASAS classification criteria<sup>6</sup> (Reproduced from Rudwaleit.<sup>12</sup>)****A. Types of findings required for definition of sacroiliitis by MRI**

- ▶ Active inflammatory lesions of the SI joints (reflecting active sacroiliitis) are required for the definition of "sacroiliitis on MRI" as one of the two imaging items in the ASAS classification criteria for axial SpA.
- ▶ BME (STIR) or osteitis (T1 post-gadolinium) highly suggestive of SpA must be clearly present and located in the typical anatomical areas (subchondral or periarticular bone marrow).
- ▶ The sole presence of other active inflammatory lesions such as synovitis, enthesitis or capsulitis without concomitant BME/osteitis is not sufficient for the definition of sacroiliitis on MRI.
- ▶ Structural lesions such as fat deposition, sclerosis, erosions or bony ankylosis are likely to reflect previous inflammation. At this time, however, the consensus group felt that the sole presence of structural lesions without concomitant BME/osteitis does not suffice for the fulfilment of sacroiliitis on MRI in the ASAS classification criteria for axial SpA.

**B. Amount of signal required**

- ▶ If there is only one signal (lesion) per MRI slice suggesting active inflammation, the lesion should be present on at least two consecutive slices. If there is more than one signal (lesion) on a single slice, one slice may be sufficient.

**II. MRI OF THE SPINE IN PATIENTS WITH SPONDYLOARTHRITIS****Table 3** Typical sites of active inflammation and chronic changes of the spine in spondyloarthritis

Location	Description
Spondylitis (involvement of vertebral bodies)	Typically located within bone marrow at one or more of the four corners of vertebral bodies. If located at the corners: spondylitis anterior (= Romanus lesion) or spondylitis posterior
Spondylodiscitis (involvement of intervertebral discs)	Located within bone marrow at cortical plate adjacent to intervertebral disc (Andersson lesion)
Arthritis of zygoapophyseal joints (facet joint arthritis)	Any facet joint from C2 to S1 may be involved; usually associated with bone marrow oedema within spinal pedicles (posterior of spinal canal)
Arthritis of costovertebral (CV) joints	Any CV joints from Th1 to Th12 may be involved; associated with bone marrow oedema near CV joint, extending to pedicles, posterior aspect of vertebral bodies (lateral of spinal canal) and neighbouring rib
Enthesitis of spinal ligaments	Possibly affected entheses: supraspinal ligament, interspinal ligaments, ligamenta flava
Syndesmophytes/ankylosis	Bridging (at the corners of the vertebral bodies) or fusion (new bone formation within the intervertebral disks) occurs in long-standing disease.

### Typical active inflammatory and chronic lesions of the spine in axial spondyloarthritis

**Figure 1** Spondylitis anterior and posterior (arrows) in three different MRI sequences: (A) T1 pre-gadolinium sequence, (B) T1 post-gadolinium sequence, (C) short tau inversion recovery (STIR) sequence. As a sign of inflammatory spinal lesion, the hypointense lesions in T1 are shown as hyperintense lesions after gadolinium enhancement and in the STIR sequence. By contrast, hypointensity in T1 pre-gadolinium (A) and post-gadolinium (B), or STIR (C), is considered a sign of erosion, as seen in the thoracic vertebrae of this patient with ankylosing spondylitis.



**Figure 2** Comparison of the sensitivity of the two most frequently used MRI sequences to depict inflammatory and chronic spinal lesions in patients with ankylosing spondylitis: (A) T1 pre-gadolinium sequence, (B) T1 post-gadolinium sequence, (C) short tau inversion recovery (STIR) sequence. While spinal fusion (thin arrows, here in the dorsal part of the thoracic vertebrae) is depicted better in the T1 pre-gadolinium MRI sequence, spinal inflammation (bold arrows) are only depicted either after application of gadolinium (B) or in the STIR sequence (C).



**Figure 3** Typical signs of inflammatory lesions in ankylosing spondylitis: (A) T1 pre-gadolinium sequence, (B) T1 post-gadolinium sequence. Thin arrows, spondylitis anterior (short arrows) and posterior (long arrows). Bold arrow, spondylitis anterior surrounding an erosion on the lower edge of the vertebral body. Circle, inflammation in the zygoapophyseal joint.



## Supplement

**Figure 4** A. T1 pre-gadolinium sequence. B. T1 post-gadolinium sequence. C. Short tau inversion recovery (STIR) sequence. Bold arrows, inflammatory spinal lesions. Thin arrows, fatty degenerative lesions. Inflammatory spinal lesions (bold arrows) can be seen as hypointense lesions (here surrounding erosive changes) in T1 pre-gadolinium and as hyperintense lesions in T1 post-gadolinium and STIR sequences on MRI, disease specific degenerative changes, such as fatty degeneration (thin arrows) are showing hyperintensity in T1 pre-gadolinium and hypointensity in T1 post-gadolinium and in STIR sequences.



**Figure 5** Active spondylodiscitis (bold arrow) and active spondylitis anterior (thin arrows) in the short tau inversion recovery (STIR) sequence (B) and fatty degeneration and syndesmophytes (arrow heads) in the T1 sequence (A).



**Figure 6** A. T1 sequence. B. Short tau inversion recovery (STIR) sequence. Thin arrows, spondylitis anterior; bold arrows, spondylodiscitis (Andersson lesion), erosions of vertebral body endplates surrounded by oedema. Bone marrow oedema is represented by hypointense signal in the T1 sequence and hyperintense in the STIR sequence.



**Figure 7** A. T1 pre-gadolinium sequence. B. Short tau inversion recovery (STIR) sequence. Bold arrow, spondylitis posterior in the atlas of a patient with ankylosing spondylitis, shown as hypointensity in T1 pre-gadolinium and as hyperintensity in STIR MRI. Thin arrows, fatty degeneration shown as hyperintensity in the T1 pre-gadolinium and as hypointensity in the STIR sequence.




**Figure 9** A. T1 sequence. B. Short tau inversion recovery (STIR) sequence. Bold arrow, fatty degeneration (suggested to be post-inflammatory) in the posterior edge of a vertebra shown as hyperintensity in the T1 sequence. Thin arrow, spondylitis anterior seen as hyperintensity in the STIR sequences.



**Figure 8** Ankylosis (arrows) in the cervical and the thoracic spine is better seen in the T1 sequence (A) than in the short tau inversion recovery (STIR) sequence (B).



**Figure 10** Typical active Andersson lesion as a characteristic sign in a patient with ankylosing spondylitis: T1 post-gadolinium MRI sequence.



**Figure 11** Bone marrow oedema (asterisks). (A) Hypointense in T1-weighted sequence and (B) hyperintense in short tau inversion recovery (STIR).



**Figure 12** Bone marrow oedema of a whole vertebral body and adjacent vertebrae (short tau inversion recovery (STIR)).



**Figure 13** Arrows represent bone marrow oedema at different sites of vertebral bodies (short tau inversion recovery (STIR)).




**Figure 14** A. T1-sequence. B. Short tau inversion recovery (STIR) sequence. Thin arrows, fatty degeneration in the posterior edges of the vertebrae. Bold arrow, chronic spondylodiscitis (Andersson lesion) represented by erosions of vertebral body endplates surrounded by areas of fat infiltration (hyperintense in the T1 sequence and hypointense in the STIR sequence). Arrowhead, acute spondylodiscitis represented by inflammatory bone marrow oedema (hyperintense in the STIR sequence and hypointense in the T1 sequence).




**Figure 15** Active inflammation (bone marrow oedema) of facet (bold arrows) and costovertebral (arrow heads) joints and active spondylitis posterior (thin arrows). Short tau inversion recovery (STIR) sequence.



**Figure 17** Acute inflammation of zygoapophyseal (facet) joints (arrow) in ankylosing spondylitis (short tau inversion recovery (STIR)).



**Figure 16** Inflammation of a costovertebral joint in the thoracic spine of a patient with ankylosing spondylitis (arrow): (A) T1-weighted sequence, (B) short tau inversion recovery (STIR) sequence.



**Figure 18** A. Sagittal short tau inversion recovery (STIR) sequence of thoracic spine demonstrating bone marrow oedema (arrow) in the lateral portion of the vertebral body and in the pedicle. B. Transverse T1-weighted turbo spin-echo sequence with fat saturation after contrast medium administration. Arthritis of the costovertebral joint T9 can be seen on the right (arrow). Increased signal intensity in the joint cleft, the head of the ninth rib and the bone marrow of the vertebral body on the right side indicates oedema formation (arrowheads). In addition, the adjacent soft tissue also shows increased signal intensity.



**Figure 19** A. T1-sequence. B. Short tau inversion recovery (STIR) sequence. Active spondylitis posterior and extensive inflammation involving facet and costovertebral joints (hyperintense in the STIR sequence and hypointense in the T1 sequence; bold arrows). Fatty degeneration (hyperintense in T1 sequence; thin arrows).



**Figure 21** 1: Corner bone erosions (spondylitis anterior); 2: non-corner bone erosions (Andersson lesion) of vertebral bodies (T1-weighted sequence).



**Figure 20** Non-corner bone erosions (Andersson lesion) (arrow) of vertebral bodies (T1-weighted sequence).



**Figure 22** Insufficiency fracture as a consequence of chronic spondylodiscitis (Andersson II lesion) (arrows) in ankylosing spondylitis (T1-weighted sequence).



**Figure 23** Post-inflammatory fatty changes (arrows) of vertebral bodies (T1-weighted sequence).

#### Pitfalls in assessment of active inflammatory and chronic spinal lesions



**Figure 24** Pitfalls in assessment of inflammatory spinal lesions by using MRI: (A) T1-weighted sequence, (B) short tau inversion recovery (STIR) sequence. Bold arrow, haemangioma in a typical position and shape. Thin arrows, fatty degeneration as a sign of degenerative lesion.





**Figure 25** Pitfalls in assessment of inflammatory spinal lesions by using MRI: (A) T1-weighted sequence, (B) short tau inversion recovery (STIR) sequence. Typical position and shape of a blood vessel (arrow) in the middle of the vertebral body.



**Figure 26** Pitfalls in assessment of inflammatory spinal lesions by using MRI: (A) T1 post-gadolinium sequence, (B) short tau inversion recovery (STIR) sequence. In this case, inflammation did not occur on the basis of ankylosing spondylitis but due to a bacterial infection. The definite diagnosis can be made based on the combination of patient history, clinical symptoms and laboratory results. As a typical sign of bacterial spondylodiscitis on MRI, the border between vertebral body and intervertebral disc is disrupted and coalesced (arrow).

## Supplement

**Figure 27** Erosive osteochondrosis (Modic lesion) as a typical pitfall of inflammatory lesion when interpreting inflammatory changes in patients with ankylosing spondylitis: (A) T1 pre-gadolinium sequence, (B) T1 post-gadolinium sequence, (C) short tau inversion recovery (STIR) sequence. In the present case, a diagnostic differentiation between ankylosing spondylitis (AS)-specific and non-AS-specific changes, only based on MRI results, is not possible. The diagnostic approach should include patient history, clinical signs and symptoms indicating AS or mechanical back pain, plain radiographs of the sacroiliac joints and laboratory results.



**Figure 28** Pitfalls in assessment of inflammatory spinal lesions by using MRI: severe mechanical erosive osteochondritis (Modic lesion) (arrows) (T1-weighted sequence); surrounded by fatty degeneration of the bone marrow L5/S1; (48-year-old man, chronic low back pain for 1 year).

### PART C: X RAYS

x Rays of sacroiliac joints and spine have been used since the 1930s for diagnosis and staging of patients with AS. In contrast to MRI, x rays can only detect chronic bony changes (damage), which are the consequence of inflammation and not inflammation itself. Therefore, x rays are not suitable for early diagnosis of spondyloarthritis but are still the method of choice for the detection of chronic changes, and as such are widely used for diagnostic purposes in patients with already established disease (modified New York criteria for SI joints). Chronic changes of the spine, especially syndesmophytes, are not part of current classification or diagnostic criteria for AS because the disease nearly always starts in the SI joints, and the presence of spinal syndesmophytes with radiologically normal SI joints is a rare, although possible, event. While early destructive changes such as erosions can also be seen by x rays, this method is mostly superior to MRI for the detection of new bone formation such as ankylosis and syndesmophytes.

Different approaches have been proposed for the radiological investigation of the SI joints with the intention to get an optimal view of this irregularly-shaped joint. None of them have been shown to be clearly superior. ASAS recommends performing x rays of the whole pelvis because this allows the assessment of the hip joints as well as the SI joints, which are relatively frequently affected in spondyloarthritis. In order to show a clearer view of the SI joints, in most of the images in this handbook the hip joints are not shown. Regarding the spine, x rays of the cervical and lumbar spine should be performed. Although changes in the thoracic spine are frequent, they are more difficult to detect because of the overlying lung tissue and therefore radiographs of the thoracic spine are not routinely assessed. The preferred method for scoring chronic changes of the spine in clinical studies, the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), investigates only lateral views of the cervical and lumbar spine.

### Other imaging techniques

Scintigraphy has been used for many decades for the detection for active inflammation in patients with SpA, but no longer plays a role in diagnosis and management of patients with SpA because of limited sensitivity and specificity<sup>13</sup> and has been replaced by MRI. Chronic bony changes can be better detected by computed tomography (CT) in comparison to x rays. However, CT is rarely used because of a much higher radiation exposure. It can be helpful in the differential diagnosis of diffuse idiopathic skeletal hyperostosis (DISH, or Forestier disease; see fig 40). Active inflammatory changes can also not be seen by CT, and fatty degeneration of the bone marrow (as an early sign of chronic changes) is only detectable by MRI and not by CT. It has to be seen in the future whether MRI, as another tomography technique, can replace CT in the assessment of chronic bony changes. Therefore, images of scintigraphy and CT (only exception: fig 40) have not been included in this handbook.

### X RAYS OF THE SACROILIAC JOINTS IN PATIENTS WITH SPONDYLOARTHRITIS

**Box 22 Radiological criterion according to the modified New York criteria for AS (1984)<sup>3</sup> (see also Part A, Box 1)**

- ▶ Sacroiliitis grade  $\geq 2$  bilaterally or grade 3–4 unilaterally.

**Box 23 Grading of radiographic sacroiliitis (1966)<sup>14</sup>**

- ▶ Grade 0: normal.
- ▶ Grade 1: suspicious changes.
- ▶ Grade 2: minimal abnormality—small localised areas with erosion or sclerosis, without alteration in the joint width.
- ▶ Grade 3: unequivocal abnormality—moderate or advanced sacroiliitis with one or more of: erosions, evidence of sclerosis, widening, narrowing, or partial ankylosis.
- ▶ Grade 4: severe abnormality—total ankylosis.




**Figure 29** Normal sacroiliac (SI) joints at both sides with sharp joint margins, no sclerosis or erosions.

## Supplement



**Figure 30** Both joints show irregular joint space without sclerosis or well defined erosions (grade 1 bilaterally).



**Figure 33** Both sacroiliac (SI) joints (right more than left) show some erosions, irregular joint space and ill-defined margins. (right grade 3, left grade 2).



**Figure 31** The left sacroiliac (SI) joint does not show specific changes but the joint does not appear completely normal (grade 1). At the site of the arrow at the right SI joint there is a minimal erosion and minimal sclerosis and ill defined margins at the iliac side of the joint (grade 2).



**Figure 34** Sclerosis at the iliac side, widespread erosions, pseudowidening of the joint space, blurring of the joint margins in both sacroiliac (SI) joints (bilateral grade 3).



**Figure 32** Both sacroiliac (SI) joints show ill-defined margins, sclerosis, and especially at the left SI joint an irregular joint space (grade 2 bilaterally).



**Figure 35** Both sacroiliac (SI) joints show a complete ankylosis (grade 4 bilaterally). Additionally, the symphysis pubis (horizontal arrow) shows a partial ankylosis. At the insertion of the ligaments at the os pubis there are signs of blurry margins. The left hip shows severe joint space narrowing (vertical arrow), especially at the medial and central part with cyst formation in the acetabulum.



**Figure 36** Both sacroiliac (SI) joints show complete ankylosis (grade 4). The lower lumbar vertebrae show syndesmophytes.




**Figure 39** Differential diagnosis of ankylosing spondylitis. Irregularly-shaped right sacroiliac joint with bony bridges mimicking sacroiliitis with partial ankylosis in an older man with DISH (diffuse idiopathic skeletal hyperostosis).

#### Differential diagnosis of ankylosing spondylitis



**Figure 37** Differential diagnosis of ankylosing spondylitis. Extensive sclerosis at the iliac side of both sacroiliac (SI) joints (arrows) with completely normal SI joints. Well defined margins, no erosions, normal width. There is no sacroiliitis but bilateral osteitis condensans ilii.




**Figure 40** Differential diagnosis of ankylosing spondylitis. CT of the sacroiliac joint from the same patient with diffuse idiopathic skeletal hyperostosis (DISH) as in fig 39: right sacroiliac joint with calcified anterior joint capsule/ligament (arrow) and relatively normal sacroiliac joint configuration.




**Figure 38** Differential diagnosis of ankylosing spondylitis. Widespread sclerosis at the iliac side of the left sacroiliac (SI) joints. The SI joints have a normal joint space width and no erosions. Osteitis condensans ilii of the left SI joint (arrow) without sacroiliitis.

## X RAYS OF THE SPINE IN PATIENTS WITH SPONDYLOARTHRITIS


### Vertebral bodies



**Figure 41** Typical x ray changes of the spine in ankylosing spondylitis: shiny corners, squaring of the vertebral bodies and syndesmophytes.




**Figure 42** The two panels of the lateral lumbar spine were taken with a 2-year interval. At baseline indicated with a large arrow there is a very small and thin syndesmophyte at the upper corner of lumbar 2. By 2 years later this has evolved to a bridging syndesmophyte. At the sites indicated by the smaller arrows there are already bridging syndesmophytes at baseline but they showed progression over a 2-year period.




**Figure 43** Lateral lumbar spine at 4-year interval. At baseline there are syndesmophytes indicated by the arrow at the lower corner of lumbar 4 and upper corner of lumbar 5. At the follow-up these syndesmophytes have formed a full bony bridge.

**Figure 44** Lateral cervical spine at 2-year intervals. At baseline bridging syndesmophyte between C7 and Th1. By 2 years later there is new bridging syndesmophyte between C6 and C7 and a thin line of ossification between C5 and C6. By a further 2 years later, almost complete ossification at the anterior side. Note that the facet joints are normal.



**Figure 45** Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).<sup>15 16</sup> A total of 24 sites are scored on the lateral cervical and lumbar spine (A): the anterior corners of the vertebrae from lower border of C2 to upper border Th1 (including) and from lower border of Th12 to upper border of S1 (including). Each corner can be scored from 0 to 3, resulting in a range from 0 to 72 for the total mSASSS. B: example of scoring according to the mSASSS. 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge.



## Osteoporotic fractures in ankylosing spondylitis




**Figure 46** Complete bamboo spine with fusion of the facet joints. Vertebral fracture at the site of the arrow.



**Figure 47** Vertebral fracture in a spine with relatively mild abnormalities due to ankylosing spondylitis, mostly in the facet joints.

## Facet joints



**Figure 48** Ankylosis of the facet joints (arrow). In the left panel in conjunction with bamboo spine formation, and in the right panel with syndesmophyte formation at a few levels.

## Diagnostic pitfalls



**Figure 49** Diagnostic pitfalls in the differential diagnosis of patients with (inflammatory) back pain. Solid large arrow, erosive osteochondrosis; Open large arrow, old lesion of Scheuermann disease; Small arrow, spondylolisthesis of L4/5 in combination with arthrosis of the facet joints (L4/5 and L5/S1).



**Figure 50** Unilateral (right) bulky bridging syndesmophytes in the thoracic spine in a patient with DISH (diffuse idiopathic skeletal hyperostosis, or Forestier disease).



**Figure 51** Wide band of calcification in front of the vertebrae (arrow) with normal facet joints. This is a typical image of DISH (diffuse idiopathic skeletal hyperostosis, or Forestier disease).



**Figure 52** Differentiation between ankylosing spondylitis specific and degenerative changes in a patient with ankylosing spondylitis. The solid arrow indicates a bridging syndesmophyte; the open arrow spondylophytes. Note: sometimes the first appearance of syndesmophytes is as osteophytes but after further growth and remodelling they become real syndesmophytes.



**Figure 53** Degenerative spine disease. Over 4 years there has been osteophyte (spondylophyte) formation at the site of the arrow. Spondylophytes are sometimes difficult to differentiate from ankylosing spondylitis (AS)-specific features such as syndesmophytes. In general, typical syndesmophytes grow in a vertical direction and typical spondylophytes in a horizontal direction.




**Figure 54** Differentiation between ankylosing spondylitis specific and degenerative changes in a patient with ankylosing spondylitis. Bony bridging at lateral cervical spine from C4 down to C7 at the sites of small arrows. Open arrow, difficult to differentiate between syndesmophyte or spondylophyte at this stage. Solid large arrow indicates fused (ankylosed) facet joints.

**PART D: CLINICAL ASSESSMENT/OUTCOME MEASUREMENTS**

In the following section the ASAS-endorsed outcome measures will be described in detail. It will start with a description of the different core sets (most recently updated version) and it will provide detailed information about the different measurement instruments. The focus is on practicality, and if necessary illustrative pictures have been added to further clarify. Assessments will be addressed domain-wise, which means that measures of disease activity will be discussed separately from measures of spinal mobility, or scoring methods for radiographic progression.

There is also a detailed overview of validated ASAS-endorsed response criteria and how to use them in clinical trials, and the newly developed ASDAS formulae will be presented.

**Box 24 ASAS/OMERACT core domains for ankylosing spondylitis<sup>17</sup>****Table 4** Assessment of SpondyloArthritis international Society (ASAS) core set for disease-controlling antirheumatic treatments (DC-ART)<sup>17</sup>

Domain	Instrument
Function	BASFI
Pain	NRS/VAS (last week/spine/at night due to AS) NRS/VAS (last week/spine/due to AS)
Spinal mobility	Chest expansion Modified Schober Occiput to wall Cervical rotation lateral spinal flexion or BASMI
Patient global	NRS/VAS (global disease activity last week)
Peripheral joints and entheses	Number of swollen joints (44-joint count)  Validated enthesitis scores, such as MASES, San Francisco and Berlin
x Ray spine	Lateral lumbar spine and lateral cervical spine
Stiffness	NRS/VAS (duration of morning stiffness/spine/last week)
Acute phase reactants	C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)
Fatigue	Fatigue question BASDAI

AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; NRS, numerical rating scale 0–10; VAS, visual analogue scale 0–100.

Adapted with permission from *J Rheumatol*.

**Table 5** Assessment of SpondyloArthritis international Society (ASAS) core set for symptom modifying antirheumatic drugs (SM-ARD) and physical therapy<sup>17</sup>

Domain	Instrument
Function	BASFI
Pain	NRS/VAS (last week/spine/at night due to AS) NRS/VAS-last week-spine-due to AS
Spinal mobility	Chest expansion Modified Schober Occiput to wall Cervical rotation Lateral spinal flexion or BASMI
Patient global	NRS/VAS (global disease activity last week)
Stiffness	NRS/VAS (duration of morning stiffness/spine/last week)
Fatigue	Fatigue question BASDAI

AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; NRS, numerical rating scale 0–10; VAS, visual analogue scale 0–100.

Adapted with permission from *J Rheumatol*.

**Table 6** Assessment of SpondyloArthritis international Society (ASAS) core set for clinical record keeping<sup>17</sup>

Domain	Instrument
Function	BASFI
Pain	NRS/VAS (last week/spine/at night due to AS) NRS/VAS (last week/spine/due to AS)
Spinal mobility	Chest expansion Modified Schober Occiput to wall Cervical rotation Lateral spinal flexion or BASMI
Patient global	NRS/VAS (global disease activity last week)
Peripheral joints and entheses	Number of swollen joints (44-joint count)  Validated enthesitis score, such as MASES, San Francisco and Berlin
Stiffness	NRS/VAS (duration of morning stiffness/spine/last week)
Acute phase reactants	C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)
Fatigue	Fatigue question BASDAI

AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; NRS, numerical rating scale 0–10; VAS, visual analogue scale 0–100.


Adapted with permission from *J Rheumatol*.

## Box 25 Spinal pain

- Two questions (on average last week), visual analogue scale (VAS) or numerical rating scale (NRS):

- How much pain of your spine due to AS do you have?
- How much pain of your spine due to AS do you have at night?


ASAS prefers to use an NRS.



## Box 26 Patient global


- How active was your spondylitis on average during the last week? (VAS, NRS)

ASAS prefers to use an NRS.



## Box 27 Stiffness spine

- How long does your morning stiffness last from the time you wake up? (NRS) (same as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 6, see Box 28)



Box 28 BASDAI on a numerical rating scale<sup>18</sup> (Adapted with permission from *J Rheumatol.*)

Alternatively, a VAS between 0 and 100 can be used, except question 6. ASAS prefers to use an NRS. Calculation of BASDAI: compute the mean of questions 5 and 6. Calculate the sum of the values of question 1–4 and add the result to the mean of questions 5 and 6. Divide the result by 5.

## NRS BASDAI

Please tick the box which represents your answer.

All questions refer to last week (ie  10).

- Fatigue**
- 1 How would you describe the overall level of fatigue/tiredness you have experienced?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- None Very severe

- Spinal pain**
- 2 How would you describe the overall level of AS neck, back or hip pain you have had?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- None Very severe

- Peripheral arthritis**
- 3 How would you describe the overall level of pain/swelling in joints other than neck, back or hips you have had?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- None Very severe

- Enthesitis**
- 4 How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- None Very severe

- Intensity of morning stiffness**
- 5 How would you describe the overall level of morning stiffness you have had from the time you wake up?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- None Very severe

- Duration of morning stiffness**
- 6 How long does your morning stiffness last from the time you wake up?
- |   |   |   |   |   |   |   |   |   |   |    |
|---|---|---|---|---|---|---|---|---|---|----|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|----|
- 0 h 1 h 2 or more h


$$\text{BASDAI} = \frac{Q1 + Q2 + Q3 + Q4 + \left(\frac{Q5 + Q6}{2}\right)}{5}$$

**Box 29 Bath Ankylosing Spondylitis Functional Index (BASFI)<sup>19</sup> (Adapted with permission from *J Rheumatol*.)**

Items to be scored by the patient:

- ▶ Putting on your socks or tights without help or aids (eg, sock aid).
- ▶ Bending forward from the waist to pick up a pen from the floor without an aid.
- ▶ Reaching up to a high shelf without help or aids (eg, helping hand).
- ▶ Getting up out of an armless dining room chair without using your hands or any other help.
- ▶ Getting up off the floor without help from lying on your back.
- ▶ Standing unsupported for 10 min without discomfort.
- ▶ Climbing 12 to 15 steps without using a handrail or walking aid. One foot at each step.
- ▶ Looking over your shoulder without turning your body.
- ▶ Doing physically demanding activities (eg, physiotherapy, exercises, gardening or sports).
- ▶ Doing a full day's activities, whether it be at home or at work.

The BASFI is the mean of 10 item scores completed on a numerical rating scale.



Alternatively, a VAS between 0 and 100 can be used. ASAS prefers to use an NRS.

**Box 30 Bath Ankylosing Spondylitis Metrology Index (BASMI)<sup>20-22</sup>**

- ▶ Five clinical measurements that reflect axial mobility:
  - tragus to wall
  - lumbar flexion
  - cervical rotation
  - lumbar side flexion
  - intermalleolar distance.
- ▶ Grading 0–2 or grading 0–10 or linear function.
- ▶ Total score 0–10.

**Table 7** Bath Ankylosing Spondylitis Metrology Index (BASMI) 3-point answer scale<sup>21</sup>

	0	1	2
	Mild	Moderate	Severe
Lateral lumbar flexion (cm)	>10 cm	5–10 cm	<5 cm
Tragus to wall distance (cm)	<15 cm	15–30 cm	>30 cm
Lumbar flexion (modified Schober) (cm)	>4 cm	2–4 cm	<2 cm
Maximal intermalleolar distance (cm)	>100 cm	70–100 cm	<70 cm
Cervical rotation (°)	>70°	20–70°	<20°

The sum of the five assessments gives the BASMI 3 result.  
Reproduced with permission from *J Rheumatol*.

**Table 8** Bath Ankylosing Spondylitis Metrology Index (BASMI) 11-point answer scale<sup>22</sup>

Points	Lateral flexion*	TTW*	Modified Schober*	IMD*	Cervical rotation†
0	≥20	≤10	≤7.0	≥120	≥85
1	18–20	10–12.9	6.4–7.0	110–119.9	76.6–85
2	15.9–17.9	13–15.9	5.7–6.3	100–109.9	68.1–76.5
3	13.8–15.8	16–18.9	5.0–5.6	90–99.9	59.6–68
4	11.7–13.7	19–21.9	4.3–4.9	80–89.9	51.1–59.5
5	9.6–11.6	22–24.9	3.6–4.2	70–79.9	42.6–51
6	7.5–9.5	25–27.9	2.9–3.5	60–69.9	34.1–42.5
7	5.4–7.4	28–30.9	2.2–2.8	50–59.9	25.6–34
8	3.3–5.3	31–33.9	1.5–2.1	40–49.9	17.1–25.5
9	1.2–3.2	34–36.9	0.8–1.4	30–39.9	8.6–17
10	≤1.2	≥37	≥0.7	≤30	≤8.5

The average score of the five assessments gives the BASMI 11 result.

\*Measurement in cm; †measurement in degrees.

IMD, intermalleolar distance; TTW, tragus to wall.

Reproduced with permission from *J Rheumatol*.

**Table 9** Bath Ankylosing Spondylitis Metrology Index (BASMI) linear function<sup>20</sup>

Function	For...
$S = (21.1 \text{ cm} - A)/2.1 \text{ cm}$	Lateral lumbar flexion (mean right/left)
$S = (A - 8 \text{ cm})/3 \text{ cm}$	Tragus to wall distance (mean right/left)
$S = (7.4 \text{ cm} - A)/0.7 \text{ cm}$	Lumbar flexion (modified Schober)
$S = (124.5 \text{ cm} - A)/10 \text{ cm}$	Maximal intermalleolar distance
$S = (89.3^\circ - A)/8.5^\circ$	Cervical rotation angle (mean right/left)

The average score of the five assessments gives the BASMI linear result. The additional condition  $0 \leq S \leq 10$  is always applied. A, result of assessment.

Box 31 BASMI linear function sheet<sup>20</sup>


## BASMI

Combined index to assess the spinal mobility  
in patients with ankylosing spondylitis

Name: \_\_\_\_\_


Date: \_\_\_\_\_

## ① Lateral spinal flexion




Mean of  
right/left

## ② Tragus-to-wall distance




Mean of  
right/left


## ③ Lumbar flexion (modified Schober)




## ④ Maximal intermalleolar distance




## ⑤ Cervical rotation




BASMI:  
(average of 5 scores)


## Box 32 Spinal mobility measures

- ▶ Cervical rotation\*†
- ▶ Lateral spinal flexion\*†
- ▶ Modified Schober\*†
- ▶ Intermalleolar distance\*
- ▶ Tragus to wall distance\*
- ▶ Occiput to wall distance†
- ▶ Chest expansion†
- ▶ BASMI<sup>†20-22</sup>

\*Included in the BASMI; †included in core set.

**Supplement****Box 33 Modified Schober**

- ▶ Patient must be standing erect.
- ▶ Mark an imaginary line connecting both posterior superior iliac spines (close to the dimples of Venus) (A).
- ▶ The next mark is placed 10 cm above (B).
- ▶ The patient bends forward maximally: measure the difference (C).
- ▶ Report the increase (in cm to the nearest 0.1 cm).
- ▶ The better of two tries is recorded.



**Box 34 Lateral spinal flexion**

- ▶ Patient's heels and back rest against the wall. No flexion in the knees, no bending forward.
- ▶ Place a mark on the thigh (A1), bend sideways without bending knees or lifting heels (A2), place a second mark and record the difference (A3).
- ▶ Alternatively, measure the distance between the patient's middle fingertip and the floor before (B1) and after bending sideways (B2), and record the difference.
- ▶ The better of two tries is recorded for left and right separately. The mean of left and right is reported for lateral spinal flexion (in cm to the nearest 0.1 cm).




## Supplement

**Box 35 Occiput to wall (grey arrow) and tragus to wall (white arrow)**

- ▶ Patient's heels and back rest against the wall.
- ▶ Chin at usual carrying level.
- ▶ Maximal effort to touch the head against the wall.
- ▶ Report the better of two tries in cm (eg, 10.2 cm).


**Box 36 Cervical rotation**

- ▶ The patient sits straight on a chair, chin level, hands on the knees.
- ▶ The assessor places a goniometer at the top of the head in line with the nose (A).
- ▶ The assessor asks to rotate the neck maximally to the left, follows with the goniometer, and records the angle between the sagittal plane and the new plane after rotation (B).
- ▶ A second reading is taken and the better of the two is recorded for the left side.
- ▶ The procedure is repeated for the right side.
- ▶ The mean of left and right is recorded in degrees (0–90°).




**Box 37 Intermalleolar distance**

- ▶ The patient is lying down (A) with the legs separated as far as possible with knees straight and toes pointing upwards (preferred method).
- ▶ Alternatively, the patient stands (B) and separates the legs as far as possible.
- ▶ The distance between the medial malleoli is measured.

**Box 38 Chest expansion (not included in BASMI)**


- ▶ The patient has their hands resting on or behind the head.
- ▶ Measure at fourth intercostal level anteriorly.
- ▶ Difference between maximal inspiration and expiration in cm is recorded (eg, 4.3 cm).
- ▶ Report the better of two tries.




## Supplement

## Box 39 Number of swollen joints

- ▶ 44 joints
- ▶ No grading
- ▶ Range from 0 to 44.

Box 40 Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)<sup>23</sup>

- ▶ 13 Sites:
  - Costochondral 1 right/left (a)
  - Costochondral 7 right/left (b)
  - Spina iliaca anterior superior right/left (c)
  - Crista iliaca right/left (d)
  - Spina iliaca posterior right/left (e)
  - Processus spinosus L5 (f)
  - Achilles tendon, proximal insertion right/left (g).
- ▶ No grading
- ▶ All sites are scored as 0 or 1
- ▶ The MASES is the sum of all site scores (from 0 to 13).

Box 41 Parameters used for the ASDAS<sup>24</sup>

- 1) Total back pain (BASDAI question 2, see Box 28)
- 2) Patient global of disease activity (see Box 26)
- 3) Peripheral pain/swelling (BASDAI question 3, see Box 28)
- 4) Duration of morning stiffness (BASDAI question 6, see Box 28)
- 5) C-reactive protein (CRP) in mg/litre (or erythrocyte sedimentation rate (ESR)).

**Box 42 Calculation of the ASDAS<sup>24</sup>**

$ASDAS_{CRP} = 0.121 \times \text{total back pain} + 0.110 \times \text{patient global} + 0.073 \times \text{peripheral pain/swelling} + 0.058 \times \text{duration of morning stiffness} + 0.579 \times \ln(\text{CRP} + 1)$ .

$ASDAS_{ESR} = 0.113 \times \text{patient global} + 0.293 \times \sqrt{ESR} + 0.086 \times \text{peripheral pain/swelling} + 0.069 \times \text{duration of morning stiffness} + 0.079 \times \text{total back pain}$ .

$ASDAS_{CRP}$  is preferred, but the  $ASDAS_{ESR}$  can be used in case CRP data are not available. CRP in mg/litre; all patient assessments on a 10 cm scale.

**Box 43 mSASSS<sup>16</sup>**

(For more details see Part C, fig 45.)

- ▶ Lateral view lumbar and cervical spine
- ▶ Anterior sites of the vertebrae are scored:
  - squaring (1 scoring point)
  - erosions (1 scoring point)
  - sclerosis (1 scoring point)
  - syndesmophytes (2 scoring points)
  - bridging syndesmophytes (3 scoring points)
- ▶ Only squaring or erosions or sclerosis can be scored per site
- ▶ Score range 0–72.

**Box 44 ASAS 20 improvement criteria<sup>25</sup>**

- ▶ Four domains:
  - Patient global (see Box 26)
  - Pain (see Box 25)
  - Function (see Box 29)
  - Inflammation (mean of BASDAI questions 5 and 6, see Box 28).
- ▶ Improvement of  $\geq 20\%$  and  $\geq 1$  unit in at least 3 domains on a scale of 10.
- ▶ No worsening of  $\geq 20\%$  and  $\geq 1$  unit in remaining domain on a scale of 10.

**Box 45 ASAS partial remission criteria<sup>25</sup>**

- ▶ Four domains:
  - Patient global (see Box 26)
  - Pain (see Box 25)
  - Function (see Box 29)
  - Inflammation (mean of BASDAI questions 5 and 6, see Box 28).
- ▶ A value not above 2 units in each of the domains on a scale of 10.

**Box 46 ASAS 40 improvement criteria<sup>26</sup>**


- ▶ Four domains:
  - Patient global (see Box 26)
  - Pain (see Box 25)
  - Function (see Box 29)
  - Inflammation (mean of BASDAI questions 5 and 6, see Box 28).
- ▶ Improvement of  $\geq 40\%$  and  $\geq 2$  unit in at least 3 domains on a scale of 10.
- ▶ No worsening at all in remaining domain.

**Box 47 ASAS 5/6 improvement criteria<sup>26</sup>**

- ▶ Six domains:
  - Patient global (see Box 26)
  - Pain (see Box 25)
  - Function (see Box 29)
  - Inflammation (mean of BASDAI questions 5 and 6, see Box 28)
  - CRP
  - Spinal mobility (lateral spinal flexion, see Box 34).
- ▶ Improvement of  $\geq 20\%$  in at least five domains.

**PART E: MANAGEMENT RECOMMENDATIONS**

By using a combined approach of a thorough analysis of the current literature and organising a meeting of international spondyloarthritis experts, ASAS has developed the first international criteria for the management of AS in general and also recommendations for the treatment of AS with tumour necrosis factor (TNF) blockers. At the time of the development of these recommendations, sufficient data were only available for patients with AS normally fulfilling the modified New York criteria. In the light of the recently developed new ASAS criteria for axial SpA (also including patients in the early non-radiographic phase of their disease) and of recent results showing an at least equal efficacy of TNF blockers in the treatment of non-radiographic axial SpA in comparison to established AS, these recommendations must and will be extended to early SpA in the near future.

Box 48 ASAS/EULAR recommendations for the management of AS<sup>27</sup>**Table 10** Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of ankylosing spondylitis (AS)<sup>27</sup>

No.	Proposition
1	Treatment of AS should be tailored according to: Current manifestations of the disease (axial, peripheral, entheselial, extra-articular symptoms and signs) Level of current symptoms, clinical findings and prognostic indicators: Disease activity/inflammation Pain Function, disability, handicap Structural damage, hip involvement, spinal deformities General clinical status (age, sex, comorbidity, concomitant drugs) Wishes and expectations of the patient
2	Disease monitoring of patients with AS should include patient history (for example, questionnaires), clinical parameters, laboratory tests and imaging, all according to the clinical presentation, as well as the ASAS core set; the frequency of monitoring should be decided on an individual basis depending on symptoms, severity and drug treatment.
3	Optimal management of AS requires a combination of non-pharmacological and pharmacological treatments
4	Non-pharmacological treatment of AS should include patient education and regular exercise. Individual and group physical therapy should be considered. Patient associations and self-help groups may be useful.
5	NSAIDs are recommended as first line drug treatment for patients with AS with pain and stiffness. In those with increased GI risk, non-selective NSAIDs plus a gastroprotective agent, or a selective COX-2 inhibitor could be used.
6	Analgesics, such as paracetamol and opioids, might be considered for pain control in patients in whom NSAIDs are insufficient, contraindicated and/or poorly tolerated.
7	Corticosteroid injections directed to the local site of musculoskeletal inflammation may be considered. The use of systemic corticosteroids for axial disease is not supported by evidence.
8	There is no evidence for the efficacy of DMARDs, including sulfasalazine and methotrexate, for the treatment of axial disease. Sulfasalazine may be considered in patients with peripheral arthritis.
9	Anti-TNF treatment should be given to patients with persistently high disease activity despite conventional treatments according to the ASAS recommendations. There is no evidence to support the obligatory use of DMARDs before, or concomitant with, anti-TNF treatment in patients with axial disease.
10	Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent of age. Spinal surgery, for example, corrective osteotomy and stabilisation procedures, may be of value in selected patients.

COX-2, cyclo-oxygenase 2; DMARDs, disease-modifying antirheumatic drugs; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.

**Table 11** First update of the international Assessment of SpondyloArthritis international Society (ASAS) consensus statement for the use of anti-tumour necrosis factor (TNF)<sup>28</sup>

Factor	Criteria
<b>Patient selection:</b>	
Diagnosis	Patients normally fulfilling modified New York criteria for definitive ankylosing spondylitis Modified New York criteria 1984 <sup>3</sup> Radiological criterion: sacroiliitis, grade $\geq$ II bilaterally or grade III to IV unilaterally Clinical criteria (two of the following three): low back pain and stiffness for more than 3 months which improves with exercise but is not relieved by rest; limitation of motion of the lumbar spine in the sagittal and frontal planes; limitation of chest expansion relative to normal values correlated for age and sex
Active disease	Active disease for $\geq$ 4 weeks BASDAI $\geq$ 4 (0–10) and an expert* opinion†
Treatment failure	All patients should have had adequate therapeutic trials of at least two NSAIDs. An adequate therapeutic trial is defined as: Treatment for at least 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated Treatment for <3 months where treatment was withdrawn because of intolerance, toxicity, or contraindications Patients with pure axial manifestations do not have to take DMARDs before anti-TNF treatment can be started Patients with symptomatic peripheral arthritis should have an insufficient response to at least one local corticosteroid injection if appropriate Patients with persistent peripheral arthritis must have had a therapeutic trial of sulfasalazine‡ Patients with symptomatic enthesitis must have failed appropriate local treatment
Contraindications	Women who are pregnant or breast feeding; effective contraception must be practised Active infection Patients at high risk of infection including: Chronic leg ulcer Previous tuberculosis (note: please follow local recommendations for prevention or treatment) Septic arthritis of a native joint within the past 12 months Sepsis of a prosthetic joint within the past 12 months, or indefinitely if the joint remains in situ Persistent or recurrent chest infections Indwelling urinary catheter History of lupus or multiple sclerosis Malignancy or pre-malignancy states excluding: Basal cell carcinoma Malignancies diagnosed and treated more than 10 years previously (where the probability of total cure is very high)
<b>Assessment of disease:</b>	
ASAS core set for daily practice	Physical function (BASFI) Pain (NRS/VAS, past week, spine at night, from ankylosing spondylitis and NRS/VAS, past week, spine, from ankylosing spondylitis) Spinal mobility (chest expansion, modified Schober, occiput to wall distance and lateral lumbar flexion) Patient global assessment (NRS/VAS, past week) Stiffness (duration of morning stiffness, spine, past week) Peripheral joints and entheses (number of swollen joints (44 joints count), enthesitis score such as MASES, Berlin, or San Francisco) Acute phase reactants (ESR or CRP) Fatigue (NRS/VAS)
BASDAI	NRS/VAS overall level of fatigue/tiredness, past week NRS/VAS overall level of ankylosing spondylitis neck, back or hip pain, past week NRS/VAS overall level of pain/swelling in joints other than neck, back or hips, past week NRS/VAS overall discomfort from any areas tender to touch or pressure, past week VAS overall level of morning stiffness from time of awakening, past week Duration and intensity (VAS) of morning stiffness from time of awakening (up to 120 min)
Assessment of response:	
Responder criteria	BASDAI: 50% relative change or absolute change of 20 mm (on a scale between 0 and 100) and expert opinion in favour of continuation
Time of evaluation	Between 6 and 12 weeks

\*The expert is a doctor, usually a rheumatologist, with expertise in ankylosing spondylitis and the use of biological agents (expert should be locally defined); †the expert should consider clinical features (history and examination), serum acute phase reactant levels and/or imaging results, such as radiographs demonstrating rapid progression or MRI indicating ongoing inflammation; ‡sulfasalazine: treatment for at least 4 months at standard target dose or maximally tolerated dose unless contraindicated or not tolerated. Treatment for less than 4 months, where treatment was withdrawn because of intolerance or toxicity or contraindicated. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale (all VAS can be replaced by a numerical rating scale (NRS)).

**Acknowledgements:** We are grateful to Anne Grethe Jurik, Mikkel Østergaard and Herman Mielants for providing images and/or participating in the discussion on the definition of positive MRIs. We would like to thank Janis Vahldiek and Georg Heine for the excellent technical assistance.

**Competing interests:** None declared.

## REFERENCES

- Rudwaleit M**, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. *Ann Rheum Dis* 2004;**63**:535–43.
- Rudwaleit M**, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis Rheum* 2005;**52**:1000–8.
- van der Linden S**, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;**27**:361–8.
- Amor B**, Dougados M, Mijiyawa M. Criteres de classification des spondylarthropathies [in French]. *Rev Rhum Mal Osteoartic* 1990;**57**:85–9.
- Dougados M**, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, *et al*. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum* 1991;**34**:1218–27.
- Rudwaleit M**, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, *et al*. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009;**68**:777–83.
- Sieper J**, van der Heijde D, Landewe R, Brandt J, Burgos-Vargas R, Collantes-Estevez E, *et al*. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). *Ann Rheum Dis* 2009;**68**:784–8.
- Calin A**, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. *JAMA* 1977;**237**:2613–4.
- Rudwaleit M**, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum* 2006;**54**:569–78.
- Landewé RB**, Hermann KG, van der Heijde DM, Baraliakos X, Jurik AG, Lambert RG, *et al*. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. *J Rheumatol* 2005;**32**:2050–5.
- Lukas C**, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Østergaard M, *et al*. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. *J Rheumatol* 2007;**34**:862–70.
- Rudwaleit M**, Jurik A-G, Hermann K-GA, Landewé R, van der Heijde D, Baraliakos X, *et al*. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis – a consensual approach by the ASAS/OMERACT MRI Group. *Ann Rheum Dis*. In press.
- Song IH**, Carrasco-Fernandez J, Rudwaleit M, Sieper J. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. *Ann Rheum Dis* 2008;**67**:1535–40.
- Bennett P**, Burch T. *Population studies of the rheumatic diseases*. Amsterdam, The Netherlands: Excerpta Medica Foundation, 1968: 456–7.
- Wanders AJ**, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, *et al*. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. *Arthritis Rheum* 2004;**50**:2622–32.
- Creemers MC**, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. *Ann Rheum Dis* 2005;**64**:127–9.
- van der Heijde D**, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. *J Rheumatol* 1999;**26**:951–4.
- Garrett S**, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;**21**:2286–91.
- Calin A**, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing Spondylitis Functional Index. *Br J Rheumatol* 1995;**34**:793–4.
- van der Heijde D**, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. *Ann Rheum Dis* 2008;**67**:489–93.
- Jenkinson TR**, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. *J Rheumatol* 1994;**21**:1694–8.
- Jones SD**, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). *J Rheumatol* 1995;**22**:1609.
- Heuft-Dorenbosch L**, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants H, *et al*. Assessment of enthesitis in ankylosing spondylitis. *Ann Rheum Dis* 2003;**62**:127–32.
- Lukas C**, Landewé R, Sieper J, Dougados M, Davis J, Braun J, *et al*. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;**68**:18–24.
- Anderson JJ**, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum* 2001;**44**:1876–86.
- Brandt J**, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. *Ann Rheum Dis* 2004;**63**:1438–44.
- Zochling J**, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, *et al*. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2006;**65**:442–52.
- Braun J**, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;**65**:316–20.